HROWHROWHealthcare · Drug Manufacturers - Specialty & Generic

HROW Stock Forecast: Harrow, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$32
+8.81% on the day

The 9 Wall Street analysts covering Harrow, Inc. hold a median 12-month price target of $60 — +86.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 17 Nov 2026 — in the lower half.

Market cap
$1.1B
Ticker Nerd rank
42/ 100
Median analyst target
$60
Analysts covering
9
Revenue$70.7M+10.9% y/y
Operating income−$11.0M
Net income−$17.3M
Free cash flow−$10.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+9.4%
1M
+17.7%
YTD
−34.4%
1Y
−19.2%
From 52W high
−41.4%
From 52W low
+23.3%
$26
$55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HROW stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Harrow, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
42/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
93
Value
82
Volatility
50
Momentum
43
Size
42
Growth
39
Revisions
36
Accruals
36
Issuance
23

Quality (93): The business earns solid, repeatable profits on what it owns.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

HROW stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HROW, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26HROWHigh $88Median $60Low $42

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $42Median $60High $88

The green dot is the last close — the median target sits +86.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Nov 2026BTIGReiteratesBuy$63
7 Oct 2026BTIGReiteratesBuy$63
7 Oct 2026BTIGReiteratesBuy—
9 Sept 2026Leerink PartnersInitiatesOutperform$45
9 Sept 2026Leerink PartnersInitiatesOutperform—
11 Aug 2026BTIGReiteratesBuy—
11 Aug 2026BTIGReiteratesBuy$63
21 July 2026BTIGReiteratesBuy$63
21 July 2026BTIGReiteratesBuy—
13 May 2026Cantor FitzgeraldMaintainsOverweight$91 → $88
13 May 2026Cantor FitzgeraldMaintainsOverweight—
12 May 2026BTIGReiteratesBuy—
12 May 2026BTIGReiteratesBuy$63
17 Apr 2026BTIGReiteratesBuy—
7 Apr 2026B. Riley SecuritiesReiteratesBuy—
19 Mar 2026HC Wainwright & Co.ReiteratesBuy—
18 Mar 2026BTIGReiteratesBuy—
4 Mar 2026Cantor FitzgeraldMaintainsOverweight—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

HROW appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

HROW vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Harrow, Inc. returned −19.2% against +12.2% for the S&P 500, dividends included.

HROW vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26HROWS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HROW analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−105.6%
Analysts raising
0
Analysts cutting
0
Fundamentals

Harrow, Inc. (HROW) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−207.7×

Cheaper than 99% of US stocks

Price / sales
3.6×

Cheaper than 31% of US stocks

Price / book
37.4×

Cheaper than 3% of US stocks

EV / EBITDA
86.0×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
38.6%

Higher than 82% of US stocks

Earnings growth (YoY)
856.6%

Higher than 97% of US stocks

Gross margin
71.3%

Higher than 84% of US stocks

Operating margin
−2.0%

Higher than 30% of US stocks

Net margin
−9.4%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−75.5%

Higher than 16% of US stocks

Return on assets
−0.9%

Higher than 40% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Harrow, Inc. (HROW) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Harrow, Inc. has a market value of $1.1B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $275.6M. The latest quarter grew 38.6% year on year.

  • Net income over the same four quarters: −$37.2M, a −13.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.00.

  • Free cash flow in the twelve months to 30 June 2026: −$13.1M.

  • Shares outstanding: 37.5M.

  • Trailing P/E: −207.7×; forward P/E: 15.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Harrow, Inc. employs 373 people — $739K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

HROW vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
HROWHarrow, Inc.$1.1B42
AMPHAmphastar Pharmaceuticals, Inc.$1.3B94
PAHCPhibro Animal Health Corp.$1.4B92
PCRXPacira Biosciences, Inc.$1.5B100
IRWDIronwood Pharmaceuticals, Inc.$794.1M100
COLLCollegium Pharmaceutical, Inc.$794.0M72
ALVOAlvotech$1.6B32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Harrow, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HROW news & analysis

Harrow: Strong Revenue Growth And Operating Leverage Ahead

Seeking Alpha · 16 Nov 2026positive

Seeking Alpha says Harrow reported strong Q3 execution, with VEVYE and IHEEZO growing 35% and 62% sequentially, respectively. Expanded commercial coverage and a larger sales team are contributing to improved VEVYE ASP and market share gains, supporting the company’s stated $350 million 2026 revenue target.

Why it matters — The item highlights product growth and commercial expansion that are relevant to Harrow’s progress toward its 2026 revenue target.

Harrow to Participate in Two Investor Conferences in November

GlobeNewsWire · 12 Nov 2026neutral

Harrow announced that management will participate in two investor conferences in November 2026: the Craig-Hallum Alpha Select Conference on November 17 and the Jefferies Global Healthcare Conference on November 18.

Why it matters — HROW watchers may note the scheduled investor meetings and Jefferies presentation as opportunities for management to engage with investors.

Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript

Seeking Alpha · 10 Nov 2026neutral

Seeking Alpha published a transcript of Harrow, Inc.’s Q3 2026 earnings call, held November 10, 2026. The excerpt lists company executives and conference-call participants but provides no discussion of results or business developments.

Why it matters — The transcript is a source for HROW watchers, but the provided excerpt contains no substantive company updates to assess.

Harrow Q3 Earnings Call Highlights

MarketBeat · 10 Nov 2026negative

Harrow reported record third-quarter revenue and reaffirmed its full-year sales forecast, while sharply reducing its adjusted earnings outlook amid lower-than-expected margins and accelerated spending.

Why it matters — HROW watchers may note the contrast between record revenue and reaffirmed sales expectations, and a reduced earnings outlook tied to margin pressure and spending.

Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 10 Nov 2026neutral

A Zacks Investment Research item discusses Harrow’s Q3 earnings for the quarter ended September 2026, focusing on how key metrics compare with Wall Street estimates and year-ago figures.

Why it matters — HROW watchers may find the comparisons useful for assessing the quarterly results beyond revenue and EPS.

FAQ

Frequently asked questions about HROW stock

What is the HROW stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Harrow, Inc. have a median 12-month price target of $60, with estimates ranging from $42 to $88. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HROW stock a buy right now?

Of the 9 analysts covering Harrow, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Harrow, Inc. 42 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HROW?

As at 17 Nov 2026, Harrow, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).

Will HROW stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +86.8% from the last close, and Ticker Nerd's factor model ranks Harrow, Inc. 42 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HROW stock forecast for 2030?

No analyst covering Harrow, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HROW are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $42 to $88 over the next 12 months.

How has HROW stock performed over the past year?

Harrow, Inc. returned -19.2% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Harrow, Inc. do?

Harrow Inc. is an eyecare pharmaceutical company that develops, manufactures, and commercializes ophthalmic products for the U.S.

What is the latest news on HROW?

The most recent item we track (Seeking Alpha, 16 Nov 2026): "Harrow: Strong Revenue Growth And Operating Leverage Ahead". Seeking Alpha says Harrow reported strong Q3 execution, with VEVYE and IHEEZO growing 35% and 62% sequentially, respectively. Expanded commercial coverage and a larger sales team are contributing to improved VEVYE ASP and market share gains, supporting the company’s stated $350 million 2026 revenue target.

Company

About Harrow, Inc.

Harrow Inc. is an eyecare pharmaceutical company that develops, manufactures, and commercializes ophthalmic products for the U.S. market. Its portfolio includes prescription and non-prescription therapies used by eye care professionals to manage conditions affecting the front and back of the eye, such as dry eye disease, glaucoma, cataracts, retinal disorders, allergies, and infections. Harrow operates through branded pharmaceuticals and ImprimisRx, its ophthalmology-focused compounding business, giving it a broad commercial footprint across eye care settings. The company’s products are used in physician offices, clinics, and surgical environments, supporting routine treatment as well as specialized ophthalmic care. Headquartered in Nashville, Tennessee, Harrow focuses on accessible eye care solutions and a product mix that spans branded, compounded, and other ophthalmic formulations.

CEO Mr. Mark L. Baum J.D. · 373 employees · United States · https://www.harrow.com